February 2015

New Product - Blincyto

Blincyto (blinatumomab (rch)) is a bispecific T cell engager (BiTE) antibody construct that selectively binds with high affinity to CD19 (expressed on cells of B-lineage origin) and CD3 (expressed on T cells). Blincyto is indicated for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B‑precursor acute lymphoblastic leukaemia (ALL). Blincyto is contraindicated in patients with known hypersensitivity to CHO cell derived proteins. Blincyto is available as a composite pack containing a powder for injection vial (containing blinatumomab (rch) 38.5 microgram) and an IV solution stabiliser vial.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au